Metabolic or Ischemic Stroke in Succinic Semi-aldehyde Dehydrogenase Deficiency Due to the Homozygous Variant c.1343 + 1_1343 + 3delGTAinsTT in ALDH5A1

With interest we read the article by Yoganathan et al. about a 15 months-old female with succinic semi-aldehyde dehydrogenase deficiency (SSAHD), manifesting with developmental delay and language deficits, who experienced an acute-onset right hemiparesis due to a “metabolic stroke” with MRI hyperintensity on diffusion-weighted imaging (DWI) and hypointensity on corresponding apparent diffusion coefficient (ADC) maps. The lesion was interpreted as “stroke-mimic” as it had disappeared on follow-up MRI. We have the following comments and concerns.

It remains unclear what the authors mean with “metabolic stroke.” Do they mean an ischemic stroke in a patient with a metabolic disorder or do they mean a stroke-like episode (SLE)? as frequently seen in various mitochondrial disorders (MIDs). Differentiation between these entities is crucial as treatment and outcome vary considerably between the two. According to the MRI images provided in Figure 1, the lesion looks as ischemic why it is curious that the authors classify the event as “stroke-mimic.” Hyperintensity on DWI and corresponding hypointensity on ADC suggests cytotoxic edema and thus ischemic stroke. We should know after which interval the lesion completely disappeared and if any dynamic changes were observed until disappearance.

Treatment of ischemic stroke is well established, whereas the treatment of an SLE is under debate. Depending on the pathophysiological hypothesis some experts recommend the application of antiepileptic drugs (AEDs) irrespective if patients present with clinical seizures or epileptiform discharges on electroencephalography (EEG), whereas, propose the application of L-arginine, antioxidants, or steroids. We should know which treatment the index patient received and if the treatment was effective or not.

Though the patient did not present with clinical seizures and though the EEG was normal, vigabatrin was given. Since the effectivity of vigabatrin for seizures in SSAHD is questionable and since the patient never exhibited seizures, the authors should explain upon which rationale vigabatrin was applied. If the rationale was blocking off the GABA breakdown, as has been previously proposed, this should explicitly be mentioned in the discussion. Missing in the report is a discussion of whether the mild clinical improvement was attributed to vigabatrin or was interpreted as spontaneous recovery from the metabolic defect.

It is reported that the patient had hyporeflexia but that nerve conduction studies were normal. We should know if the patient also presented with muscle weakness, muscle wasting, elevated creatine-kinase (CK), and myogenic electromyography (EMG), and if the authors considered myopathy as the cause of hyporeflexia. Missing in the report is a presentation of the vascular risk factors. We should know if the individual or family history was positive.
for arterial hypertension, hyperlipidemia, diabetes, or atrial fibrillation. It should be reported if long-term ECG recording was carried out to exclude paroxysmal atrial fibrillation. We should know the results of the echocardiographic examination.

Imaging studies should be revised for cerebellar atrophy since it has been described as a cerebral manifestation of the disease.[6]

Overall, this interesting case report has a number of limitations and shortcomings which need to be solved before final conclusions can be drawn. Confirmation of the stroke as “metabolic” is required, treatment options for SLEs should be discussed, the rationale for the application of vigabatrin should be more extensively debated, and myopathy should be considered as the cause of hyporeflexia.

**Author contribution**

JF: design, literature search, discussion, first draft, FAS, CAS, RG: literature search, discussion, critical comments.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

Josef Finsterer, Carla A. Scorza¹, Fulvio A. Scorza¹, Ritwik Ghosh²

Krankenanstalt Rudolfstiftung, Vienna, Austria, ¹Disciplina de Neurociência, Escola Paulista de Medicina, Universidade Federal de São Paulo, (EPM/UNIFESP), São Paulo, Brasil, ²Department of General Medicine, Burdwan Medical College, Burdwan, West Bengal, India

**Address for correspondence:** Dr. Josef Finsterer, Postfach 20, 1180 Vienna, Austria, Europe.

E-mail: fifigs1@yahoo.de

**REFERENCES**

1. Yoganathan S, Arunachal G, Kratz L, Varman M, Thomas M, Sudhakar SV, et al. Metabolic stroke: A novel presentation in a child with succinic semialdehyde dehydrogenase deficiency. Ann Indian Acad Neurol 2020;23:113-7.

2. Finsterer J. Mitochondrial metabolic stroke: Phenotype and genetics of stroke-like episodes. J Neurol Sci 2019;400:135-41.

3. Ng YS, Bindoff LA, Gorman GS, Horvath R, Klopstock T, Mancuso M, et al. Consensus-based statements for the management of mitochondrial stroke-like episodes. Wellcome Open Res 2019;4:201.

4. Finsterer J. The metabolic more likely than the epileptogenic hypothesis explain stroke-like lesions. Wellcome Open Res 2020;(in press).

5. Gropman A. Vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency. Ann Neurol 2003;54(suppl 6):S66-72.

6. Acosta MT, Munasinghe J, Pearl PL, Gupta M, Finegersh A, Gibson KM, et al. Cerebellar atrophy in human and murine succinic semialdehyde dehydrogenase deficiency. J Child Neurol 2010;25:1457-61.

Submitted: 03-Apr-2020 Revised: 06-May-2020 Accepted: 13-Apr-2020

Published: 05-Jun-2020

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

DOI: 10.4103/aian.AIAN_246_20